Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell …

primary cancer
metastatic cancer
clear cell renal cell carcinoma
carcinoma
renal cell cancer
  • 144 views
  • 22 Dec, 2020
  • 1 location
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will

  • 0 views
  • 01 Feb, 2021
  • 6 locations
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

).), with or without s.c. aldesleukin (IL-2)). Patients diagnosed after the closure of R3 randomization will not be R4 randomized. For these patients the use of ch14.18/CHO antibody is recommended without

interleukin
high-risk neuroblastoma
filgrastim
cyclophosphamide
etoposide
  • 288 views
  • 26 Jan, 2021
  • 126 locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking …

ganglioneuroblastoma
high-risk neuroblastoma
thiotepa
tumor cells
cyclophosphamide
  • 66 views
  • 31 Mar, 2021
  • 99 locations
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body

metastatic disease
glomerular filtration rate
pd-l1
serum total bilirubin level
tumor cells
  • 21 views
  • 28 Jan, 2021
  • 1 location
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

To evaluate safety, tolerance and efficacy of TASO(TGF-2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid

  • 0 views
  • 07 May, 2021
  • 1 location
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide Aldesleukin and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab

cancer
mitomycin
interleukin-2
ipilimumab
metastasis
  • 30 views
  • 27 Jan, 2021
  • 2 locations
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

Lymphocytes (TIL) and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic biliary tract cancer. These are low-incidence cancers carry a poor prognosis. Participants will include

absolute neutrophil count
biliary cancer
gallbladder cancer
biliary tract cancer
gemcitabine
  • 26 views
  • 12 Feb, 2021
  • 1 location
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with

alt/ast
filgrastim
minor surgery
neutrophil count
cyclophosphamide
  • 12 views
  • 07 Apr, 2021
  • 1 location
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

This is a Phase 2 study in which the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with

gilbert's syndrome
metastatic uveal melanoma
clinical protocols
alopecia
neutrophil count
  • 30 views
  • 29 Apr, 2021
  • 1 location